Guangdong Zhongsheng Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd maintains a strong liquidity position, as evidenced by a current ratio of 4.24, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. However, the company's free cash flow is negative at -92.92 million CNY, which suggests that the firm is spending more on capital expenditures than it is generating in operating cash flow. The company's liquidity is assessed as medium, with a key flag indicating that net cash is negative after subtracting total debt.

In terms of profitability, the company's return on equity (ROE) is 6.8%, and its return on assets (ROA) is 5.38%. These figures are below the typical thresholds for high-performing pharmaceutical firms, suggesting that the company is not generating returns as efficiently as its peers. The gross profit margin is 55.9%, which is relatively strong, but the operating margin is only 11.8%, indicating that the company is facing significant operating expenses.

The company's revenue is concentrated in a single geographic region, primarily China, with no disclosed international operations. This concentration increases the company's exposure to local economic and regulatory risks. The company's revenue for the latest period was 2.52 billion CNY, and the mean analyst revenue estimate for the next period is 2.98 billion CNY, indicating a projected growth of approximately 18%.

The company's growth trajectory is positive, with a projected increase in revenue and earnings. The mean analyst estimate for the next period's EPS is 0.47 CNY, compared to the last actual EPS of 0.33 CNY, suggesting a potential growth of 42% in earnings. However, the company's capital expenditures are significant at 316.17 million CNY, which may impact its ability to maintain high growth rates in the long term.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The debt-to-equity ratio is 0.08, indicating a conservative capital structure with minimal reliance on debt financing. The company's governance score is relatively high at 76.79, suggesting strong corporate governance practices. However, the ESG controversies score is 100.00, indicating that the company has not been involved in any recent controversies.

Recent events and filings indicate that the company is maintaining a stable financial position. The company's free cash flow is negative, but its operating cash flow is positive at 305.20 million CNY, which suggests that the company is generating sufficient cash from operations to support its capital expenditures. The company's capital expenditures are primarily focused on expanding its production capabilities and improving its manufacturing processes.

Guangdong Zhongsheng Pharmaceutical Co Ltd (002317.SZ) has undergone a formal classification update, with its economic sector now explicitly identified as Healthcare and its primary activity defined as Pharmaceuticals. This structural clarification serves as the most material change in the company's profile, establishing a clear baseline for industry-specific analysis and peer comparison within the broader healthcare landscape. Concurrently, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is currently rated as low, suggesting a stable capital structure with minimal immediate threat of share value erosion from new issuances. This low dilution profile provides a foundational layer of security for existing shareholders, indicating that management is not aggressively leveraging equity issuance to fund operations at this stage. In contrast, liquidity risk has been assessed at a medium level. This designation highlights a moderate degree of uncertainty regarding the company's ability to meet short-term financial obligations without significant cost or delay. While not critical, this medium rating warrants attention as it suggests that cash flow management and working capital efficiency remain key operational focuses for the firm. The COMPANY_360 data indicates that the company currently has no recorded analyst coverage, index memberships, or top holder disclosures in the available dataset. This lack of external tracking metrics underscores the importance of the newly established internal risk and taxonomy classifications as the primary lenses through which the company's financial health and sector positioning are currently understood.